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OBJECTIVES: The main aim of this retrospective study was to
perform a cost-minimization analysis of long term use of
Darbepoetin-á (DARB) after switch from erythropoietin beta
(EPO-â)in treating chronic nephropathy-induced anemia in
dialysed patients. METHODS: We extracted data of 78 patients
who have been treated with EPO-â for at least 6 months and then
switched to DARB from the database of the dialysis center of the
Asti (Piedmont, Italy) hospital. From these, we selected 47
patients (23 males and 24 females) who completed a 120-weeks
follow-up treatment with DARB. All patients were treated with a
dose adjustment schedule to keep hemoglobin levels in the range
11–12 g/dl. Pre-switch EPO-â administration was thrice a week,
while DARB was administered once a week, both via intrave-
nous. Initial DARB dose has been calculated on the basis of the
theoretical 200:1 conversion factor. Drug costs were valued
according to current (October 2006) purchasing prices for the
Italian National Health System. RESULTS: The average actual
conversion factor from EPO-â to DARB at the end of 120 weeks
of follow-up resulted 280:1. The initial DARB dose, chosen on
the basis of the recommended conversion factor, induced an
excessive erythropoietic response, which was generally followed
by a gradual dose reduction. In the 24 pre-switch weeks the
average cost (SD) per patient for EPO-â was 2309.86
(1434.78) Euro. In the 120 weeks of follow-up the average cost
(SD) per patient for DARB/24 weeks ranged from a minimum
of 1487.09 (1125.51) Euro to a maximum of 2125.73 (1546.85)
Euro. The switch of 47 patients to DARB produced an overall net
saving for the dialysis center estimated in 119,540.72 Euro/120
weeks. CONCLUSION: The conversion from EPO-â to DARB
has the potential to maintain good haemoglobin control also in
the long term and induces signiﬁcant savings for the National
Health System.
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OBJECTIVES: to assess annual resource use and cost on diffuse
large B-cell lymphoma (DLBCL) treatment by CHOP (Cytoxan,
Hydroxyrubicin (Adriamycin), Oncovin (Vincristine), Pred-
nisone.), R-CHOP (Rituximab, Cytoxan, Hydroxyrubicin
(Adriamycin), Oncovin (Vincristine), Prednisone.), modiﬁed
NHL-BFM-90 (prednisone, dexamethasone, vincristine, dauno-
rubicin, doxorubicin, L-asparaginase, cyclophosphamide, cytara-
bine, methotrexate, 6-mercaptopurine, 6-thioguanine) courses.
METHODS: Cost of illness analysis was performed. Direct
medical costs (cost of drug administration, resource utilization,
duration of hospitalization) were estimated. DLBCL absolute
prevalence was 2084 patients in 2004 in Russia. We choose 120
patients with DLBCL to estimate distribution of chemotherapy
courses. Unit costs were based on detailed data from the Moscow
Medical Sechenov Academy. RESULTS: Cost of drug adminis-
tration for one patient with DLBCL received CHOP were 30,576
RUB, R-CHOP—646,278 RUB and ìNHL- BFM—90—708,911
RUB*. Cost of diagnostic DLBCL was the same for all patients
(54,339 RUB). Chemotherapy courses distribution for patients
was CHOP—54%, R-CHOP—17%, ìNHL- BFM-90—29%.
CONCLUSION: The annual cost burden for newly diagnosed
patients with DLBCL was 803 million rubles. *—The rate of
exchange was 34.77 rubles for 1 EUR.
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OBJECTIVES: Only few studies assess the health economic
burden of myelodysplastic syndromes (MDS). In Germany no
such cost study has been conducted. The annual incidence peaks
at 20–30 in 100,000 in persons over 70 years of age. Treatment
of MDS and its side effects as well as MDS-related co-morbidities
lead to intensive resource use, which increases with duration and
severity of illness. The objective of this study is to assess and
analyse costs of transfusion-dependent low/intermediate-1 risk
MDS in Germany from a payers’ perspective. METHODS: One
hundred low/intermediate-1 risk transfusion-dependent MDS
patients [non del(5q) and del(5q)] from 10 outpatient facilities
and 20 low/intermediate-1 risk transfusion-dependent del (5q)
MDS patients from a hospital-based MDS registry were identi-
ﬁed. Claims data and patient records of the previous ﬁve years
are used to collect health care utilization data of these patients
retrospectively. Publicly available tariff books and remuneration
schemes are applied to evaluate mean costs per year in 2006
EUROS. RESULTS: The intermediate cohort analysis showed no
signiﬁcant differences in the cohort characteristics between the
two groups [non-del (5q) and del(5q)] except in the number of
co-morbidities (0% vs. 45% with more than 3 co-morbidities,
respectively). Yearly costs of outpatient services are signiﬁcantly
higher in the non-del (5q) group (€1805 vs. €956 in del (5q)
patients), the yearly costs for inpatient services, medication and
transfusions are signiﬁcantly higher in the del (5q) patient group
vs. the non-del(5q) group. Mean costs are €4,345 vs. €986,
12,834 vs. €3,556, and €3,224 vs. €1,054, respectively. In total,
treatment costs of del (5q) patients amount to €21,367 compared
to €7,413 for non-del (5q) patients. Both groups show that the
main cost driver is medication. Speciﬁc subgroup analyses will be
presented. CONCLUSION: MDS leads to a high health care
utilization and resulting costs. Del(5q) patients signiﬁcantly use
more health care resources, though less outpatient care, than the
comparator group.
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OBJECTIVES: The availability of rFVIIa has improved the fea-
sibility of orthopedic surgery in hemophiliacs with high titer
inhibitors and hemophilic arthropathy, leading to reductions in
bleeding episodes and improvements in pain, function and mobil-
ity, and quality of life. This analysis explored the cost utility of
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